Contact
searchSearch
HMP Global

Psychedelics

psilocybin mushrooms in a beaker
Psychedelics Update
Compass Pathways Submits COMP360 Psilocybin Application for Treatment-Resistant Depression
11/09/2026
Maria Mantas
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed...
11/09/2026
Psych Congress Network
A lab tech handles psilocybin mushrooms in a research lab
Research Summary
Psilocybin Linked to Lower Inflammatory Markers in Parkinson Disease
11/09/2026
Brionna Mendoza
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was...
11/09/2026
Psych Congress Network
intranasal spray bottles
Research Summary
Mebufotenin Shows Rapid Antidepressant Effects in Phase 2b Trial
11/02/2026
Brionna Mendoza
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of...
11/02/2026
Psych Congress Network
An audience at a conference listens to a speaker on stage
Conference Coverage
Psych Congress 2026 Keynote Highlights Hope—and Uncertainty—for Psychedelic Therapies
09/15/2026
Brionna Mendoza
Federal agencies are expanding cooperation on psychedelic drug research and seeking public input on future implementation, but major questions about approval, infrastructure, clinician training, and patient access remain, speakers said during...
Federal agencies are expanding cooperation on psychedelic drug research and seeking public input on future implementation, but major questions about approval, infrastructure, clinician training, and patient access remain, speakers said during...
Federal agencies are expanding...
09/15/2026
Psych Congress Network
fda building sign
News
FDA Grants DT120 Second Breakthrough Designation, Now for MDD
09/09/2026
Brionna Mendoza
The US FDA has granted Breakthrough Therapy designation to DT120, an orally disintegrating lysergide tablet, for the treatment of MDD.
The US FDA has granted Breakthrough Therapy designation to DT120, an orally disintegrating lysergide tablet, for the treatment of MDD.
The US FDA has granted...
09/09/2026
Psych Congress Network
psilocybin
Research Summary
Oregon Psilocybin Program Shows Mental Health Improvements, Few Serious Reactions
08/20/2026
Maria Mantas
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s...
08/20/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
psilocybin mushrooms in a beaker
Conference Coverage
Clinicians Prepared for Evolving Psychedelic Landscape at Psych Congress Elevate
06/06/2026
Maria Mantas
Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
Experts at Elevate examined the...
06/06/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
Andrew Penn, PMHNP-BC, and Chuck Raison, MD
Insights
Psychedelic Therapies at a Turning Point: How Recent Federal Actions May Reshape Psychiatric Care
04/29/2026
Maria Mantas
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Steering Committee members Charles Raison, MD, and Andrew Penn, MS, PMHNP-BC, discuss why recent regulatory actions could mark an inflection point for psychedelic psychiatry.
Steering Committee members...
04/29/2026
Psych Congress Network

News Articles

psilocybin mushrooms in a beaker
Psychedelics Update
Compass Pathways Submits COMP360 Psilocybin Application for Treatment-Resistant Depression
11/09/2026
Maria Mantas
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed...
11/09/2026
Psych Congress Network
A lab tech handles psilocybin mushrooms in a research lab
Research Summary
Psilocybin Linked to Lower Inflammatory Markers in Parkinson Disease
11/09/2026
Brionna Mendoza
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was...
11/09/2026
Psych Congress Network
intranasal spray bottles
Research Summary
Mebufotenin Shows Rapid Antidepressant Effects in Phase 2b Trial
11/02/2026
Brionna Mendoza
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of...
11/02/2026
Psych Congress Network
psilocybin
Research Summary
Oregon Psilocybin Program Shows Mental Health Improvements, Few Serious Reactions
08/20/2026
Maria Mantas
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s...
08/20/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
a woman sits on a windowsill and looks out the window
Research Summary
Inhaled Psychedelic Therapy Shows Rapid TRD Relief in Phase 2b Trial
03/27/2026
Brionna Mendoza
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD). 
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD). 
A phase 2b randomized clinical...
03/27/2026
Psych Congress Network
psilocybin mushrooms in a beaker
Psychedelics Update
Compass Pathways Submits COMP360 Psilocybin Application for Treatment-Resistant Depression
11/09/2026
Maria Mantas
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed...
11/09/2026
Psych Congress Network
A lab tech handles psilocybin mushrooms in a research lab
Research Summary
Psilocybin Linked to Lower Inflammatory Markers in Parkinson Disease
11/09/2026
Brionna Mendoza
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was...
11/09/2026
Psych Congress Network
a woman holds a baby on her lap
Research Summary
Digital Intervention Reduces Perinatal Anxiety During Pregnancy and Postpartum
11/05/2026
Maria Mantas
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A self-led digital intervention...
11/05/2026
Psych Congress Network
intranasal spray bottles
Research Summary
Mebufotenin Shows Rapid Antidepressant Effects in Phase 2b Trial
11/02/2026
Brionna Mendoza
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of...
11/02/2026
Psych Congress Network
A clinician fills out a form on a clipboard
News
RAP-219 Meets Key Endpoints in Acute Bipolar Mania Trial
10/26/2026
Brionna Mendoza
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Investigational RAP-219 met the...
10/26/2026
Psych Congress Network
3D illustration of a brain in blue and white against a black background
Research Summary
Home Depression Protocol Proves Feasible but Shows No Added Benefit
10/21/2026
Brionna Mendoza
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
Home transcranial direct current...
10/21/2026
Psych Congress Network
a woman pours a pill from a pill bottle into her hand
Research Summary
Meta-Analysis Finds No Clear Sex Differences in Antipsychotic Efficacy
10/15/2026
Maria Mantas
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data...
10/15/2026
Psych Congress Network
Head in profile with brain visible and target over brain
Research Summary
Structural Connectivity–Guided iTBS Improves Early Depression Outcomes
10/08/2026
Brionna Mendoza
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach...
10/08/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
Only 19.1% of First-Episode Psychosis Patients Adhere to Antipsychotics
10/06/2026
Brionna Mendoza
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning...
10/06/2026
Psych Congress Network
A selection of ultraprocessed foods, including donuts, hamburgers, pizza, and fries.
News
Low-Ultraprocessed-Food Diet Linked to Lower Depression Scores
09/25/2026
Brionna Mendoza
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food...
09/25/2026
Psych Congress Network

Blogs

Blog
Psychedelics in Group Therapy for HIV Survivors Shows Promising Results
10/02/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the...
10/02/2020
Psych Congress Network
Blog
Psych Congress to Bring Psychedelic-Assisted Therapies Into Focus
09/03/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted...
09/03/2020
Psych Congress Network
Blog
Psychedelics and Wellness: What’s the Connection?
12/17/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra...
12/17/2019
Psych Congress Network
Blog
The Psychedelic Aspect of Esketamine is an Opportunity, Not a Side Effect
05/23/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the...
05/23/2019
Psych Congress Network
Blog
A Turning Point for Psychedelics?
06/06/2018
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of...
06/06/2018
Psych Congress Network
Blog
Depression as Disconnection: New Lessons From Psychedelic Psychotherapy Studies
11/02/2017
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies...
11/02/2017
Psych Congress Network
Blog
Psilocybin Studies: A New Ray of Hope for Psychiatry?
12/01/2016
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the...
12/01/2016
Psych Congress Network
Blog
Psychedelics: What to Tell Patients Today
08/25/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are...
08/25/2015
Psych Congress Network
Blog
How Psychedelics May Be Used to Accelerate Psychotherapy
08/19/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment...
08/19/2015
Psych Congress Network
Blog
Can Psychedelics Target Overly Rigid Brain Networks?
07/30/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
The idea of using these drugs as catalysts for psychotherapeutic change challenges biological psychiatry’s predominant orientation towards mental disease as something that is managed or palliated, but not cured.
The idea of using these drugs as catalysts for psychotherapeutic change challenges biological psychiatry’s predominant orientation towards mental disease as something that is managed or palliated, but not cured.
The idea of using these drugs as...
07/30/2015
Psych Congress Network
marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Rakesh Amin, MD.
Blog
Treating Schizophrenia: The Importance of Early Identification and Intervention
06/13/2023
Rakesh Amin, MD
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the...
06/13/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Ed Jones, PhD
Blog
How Our Clinicians Can Help Fix the US Health Care System
07/28/2022
Ed Jones, PhD
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the...
07/28/2022
Psych Congress Network
Ed Jones, PhD
Perspective
The Universal Behavior Model: A Comprehensive Approach to Integrated Care
07/21/2022
Ed Jones, PhD
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this...
07/21/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
Who will use it? How to Get Digital Mental Health Apps Into the Hands of Patients
04/27/2022
Steven Chan, MD, MBA; Burhan Ahmed Khan, MD
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan...
04/27/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
How to Navigate Quality Issues With Mental Health Apps
04/21/2022
Steven Chan, MD, MBA; Burhan Ahmed Khan, MD
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan...
04/21/2022
Psych Congress Network
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Blog
How New NPs Can Find Mentors
03/04/2022
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains...
03/04/2022
Psych Congress Network
Julie Bailey
Blog
How to Be a Safe Space for Someone
02/08/2022
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey,...
02/08/2022
Psych Congress Network
major depressive disorder
Blog
The Best and Worst Changes Brought On By the Pandemic
01/31/2022
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy...
01/31/2022
Psych Congress Network

Interactive Features

An illustration of a pencil marking answers on a quiz sheet.
Quiz
Intranasal Esketamine Dosage for Adult MDD
02/04/2026
Brionna Mendoza
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and...
02/04/2026
Psych Congress Network
Quiz
Quiz: Psilocybin Named Breakthrough Therapy for Which Condition?
12/10/2019
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug...
12/10/2019
Psych Congress Network
Rakesh Jain, MD, MPH
Quiz
Common Missteps in Sleep Care
10/13/2026
Maria Mantas
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with...
10/13/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Biomarker-Consistent Antidepressant Selection
10/13/2026
Maria Mantas
Can you recall how biomarker-consistent antidepressant treatment compared to biomarker-inconsistent treatment?
Can you recall how biomarker-consistent antidepressant treatment compared to biomarker-inconsistent treatment?
Can you recall how...
10/13/2026
Psych Congress Network
pencil erasers that spell out the word "quiz"
Quiz
iTBS Outcomes in MDD
09/15/2026
Maria Mantas
Can you recall how iBTS compared to sham in addressing clinician-rated depressive symptoms among adults with MDD?
Can you recall how iBTS compared to sham in addressing clinician-rated depressive symptoms among adults with MDD?
Can you recall how iBTS compared...
09/15/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
rTMS Function in MDD Treatment
09/09/2026
Brionna Mendoza
Test your treatment knowledge with this quiz!
Test your treatment knowledge with this quiz!
Test your treatment knowledge...
09/09/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Assessing VMAT2 Inhibitor Response
09/03/2026
Maria Mantas
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2...
09/03/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Assessing VMAT2 Inhibitor Response
09/03/2026
Maria Mantas
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2...
09/03/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Adjunctive Treatment Efficacy in MDD
08/26/2026
Maria Mantas
Can you recall which drug demonstrated the highest efficacy as adjunctive therapy for major depressive disorder?
Can you recall which drug demonstrated the highest efficacy as adjunctive therapy for major depressive disorder?
Can you recall which drug...
08/26/2026
Psych Congress Network
pencil erasers that spell out the word "quiz"
Quiz
Citalopram Dosing in Older Adults
08/25/2026
Maria Mantas
What is the recommended dosage of citalopram for older patients? Test your prescribing knowledge with this quiz!
What is the recommended dosage of citalopram for older patients? Test your prescribing knowledge with this quiz!
What is the recommended dosage...
08/25/2026
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network

NEW FROM PSYCH CONGRESS NP INSTITUTE

Michael Asbach and Arwen Podesta
Clinical Pearls
Making Lifestyle Interventions Practical and Accessible in MDD Care
10/29/2026
Michael Asbach, DMSc, PA-C; Arwen Podesta, MD
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych...
10/29/2026
Psych Congress NP Institute
Michael Asbach and Arwen Podesta
Clinical Pearls
Addressing Lifestyle Factors in Major Depressive Disorder
10/23/2026
Michael Asbach, DMSc, PA-C; Arwen Podesta, MD
How can clinicians incorporate lifestyle interventions into major depressive disorder (MDD) treatment alongside pharmacotherapy?
How can clinicians incorporate lifestyle interventions into major depressive disorder (MDD) treatment alongside pharmacotherapy?
How can clinicians incorporate...
10/23/2026
Psych Congress NP Institute
Kristian Dambrino, DNP, PMHNP-BC
Clinical Pearls
Exploring the Role of Dual-Mechanism and Multimodal Antidepressants in MDD Treatment
10/13/2026
Kristian Dambrino, DNP, APRN, MSN
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP,...
10/13/2026
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use